Identification of new cytokine combinations for antigen-specific T-cell therapy products via a high-throughput multi-parameter assay

Overview
The authors used a high-throughput assay to optimize cytokine conditions for VST expansion. Results showed IL-15/IL-6 was effective. These findings were validated by scaling up cultures in G-Rex® 10 devices, which produced functional T cells equivalent to standard protocols.
What this paper found
A 96-well, 13-color flow cytometry screen identified IL-15 plus IL-6 as a cytokine pair that expands cytomegalovirus-specific T cells as well as the standard IL-4 plus IL-7, while skewing products toward CD8+ cells. Using donor PBMCs pulsed with IE1 and pp65 peptide pools, one plate tested 40 cytokine combinations with only 1 × 10^7 cells. After 10 days, IL-15/IL-6 expanded CD3+ cells a median 17.1-fold over no-cytokine controls versus 13.8-fold for IL-4/IL-7; it yielded 2.8-fold more CD8+ cells, whereas IL-4/IL-7 yielded 2.1-fold more CD4+ cells. Median IFN-γ-producing CD3+ cells were 19.3% and 16.3%. In G-Rex® 10 vessels, IL-15/IL-6 cells gave 638 ± 297 IFN-γ ELISpot spots per 100,000 cells versus 555 ± 230 with IL-4/IL-7.
Note: In vitro study on donor cells; the authors observed that some donors expanded better in IL-4/IL-7 and others in IL-15/IL-6.
This demonstrates that cells grown in IL-15/IL-6 were functionally equivalent to cells grown in IL-4/IL-7 when cultured to clinical scale and that the high-throughput screening method can reliably optimize product development. — Christopher A. Lazarski, Anushree A. Datar, Emily K. Reynolds, Michael D. Keller, Catherine M. Bollard, Patrick J. Hanley, Cytotherapy
Study details
- Authors
- Christopher A. Lazarski, Anushree A. Datar, Emily K. Reynolds, Michael D. Keller, Catherine M. Bollard, Patrick J. Hanley
- Institution
- Center for Cancer and Immunology Research, Children’s National Hospital, Washington, DC, USA · Division of Allergy and Immunology, Children’s National Hospital, Washington, DC, USA · Division of Blood and Marrow Transplantation, Children’s National Hospital, Washington, DC, USA · The George Washington University Cancer Center, Washington, DC, USA
- Journal
- Cytotherapy
- Year
- 2020
- G-Rex® model(s)
- G-Rex®10
- Cell type(s)
- VST Cells
- Application area
- Infectious disease
- Study phase
- Preclinical
How G-Rex® was used
To confirm the 96-well screening results at clinical scale, 1–1.5 × 10^7 PBMCs were pulsed with IE1 and pp65 peptide libraries and cultured in G-Rex® 10 gas permeable chambers, resuspended in 1 mL of complete medium and then topped up with 29 mL of medium containing either IL-4/IL-7 or IL-15/IL-6. On day 7, 15 mL of medium was replaced with fresh medium and cytokines, and cells were cultured for 3 more days. Cells from the G-Rex® 10 vessels were then tested in IFN-γ ELISpot assays, where IL-15/IL-6 and IL-4/IL-7 products gave equivalent CMV-specific responses.
Explore related
Full citation
Lazarski CA, Datar AA, Reynolds EK, Keller MD, Bollard CM, Hanley PJ. Identification of new cytokine combinations for antigen-specific T-cell therapy products via a high-throughput multi-parameter assay. Cytotherapy. 2021;23(1):65-76.
Building a similar workflow?
Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.